ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452) and diagnostic imaging agent, Debio 0328 ([68Ga]Ga-DPI-4452)




